Cancer causes & control : CCC最新文献

{"title":"Comparative risk factors among pancreatic adenocarcinoma patients vs. neuroendocrine and other pancreatic cancer patients.","authors":"Daniel C Beachler, Lauren E Parlett, Jessica L Petrick, Stephan Lanes, John Barron, David Debono, Michael J Fisch","doi":"10.1007/s10552-026-02192-7","DOIUrl":"10.1007/s10552-026-02192-7","url":null,"abstract":"<p><strong>Purpose: </strong>Determine whether the risk factors for pancreatic ductal adenocarcinoma (PDAC) differ from other rare subtypes of pancreatic cancer, such as pancreatic neuroendocrine tumors (PNETs).</p><p><strong>Methods: </strong>In this retrospective cohort (case-only) database study, the study population was pancreatic cancer patients with histology information in the Cancer Care Quality Program between July 2014 and May 2025. Multivariate logistic regression models were developed to identify independent differences in risk factors for PNETs (vs. PDACs) and other pancreatic cancers (vs. PDACs).</p><p><strong>Results: </strong>This study included the following incident pancreatic cancer frequencies: 7,973 PDACs, 649 PNETs, and 363 other pancreatic cancers. PNETs and other pancreatic cancer patients were younger than PDACs (mean 57 and 60 vs. 62). PNET patients were more likely to have newly diagnosed diabetes prior to their pancreatic cancer diagnosis (aOR = 1.37, 95%CI = 0.98-1.97), and less likely to smoke (aOR = 0.80, 95%CI = 0.64-1.01). PNETs and other pancreatic cancers had slightly higher baseline co-morbidity scores (Charlson) than PDACs (1.7 vs. 2.6 vs. 2.8). Other pancreatic cancers were more likely to be current alcohol drinkers (aOR = 2.86, 95%CI = 1.25-6.59). Common risk factors such as obesity and family history of pancreatic cancer were similar among the three cohorts.</p><p><strong>Conclusions: </strong>This study suggests there may be different risk factors for rarer pancreatic cancer subtypes. Differences such as younger age and more alcohol use were noteworthy in the rarer pancreatic subtypes.</p>","PeriodicalId":520579,"journal":{"name":"Cancer causes & control : CCC","volume":"37 7","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum human papilloma virus detection following treatment of cervical cancer: prevalence and its correlation with recurrence.","authors":"Vinotha Thomas, John Dickson Calvin Devadasan, Neenu Oliver John, Jeba Karunya Reddy, Arvind Sathyamurthy, Dhanya Susan Thomas, Gnanadurai John Fletcher, Rajesh Kannangai, Anuradha Chandramohan, Betty Simon, Anitha Thomas, Thomas Samuel Ram, Grace Rebekah, Priya Abraham","doi":"10.1007/s10552-026-02201-9","DOIUrl":"10.1007/s10552-026-02201-9","url":null,"abstract":"<p><strong>Introduction: </strong>The detection of human papilloma virus (HPV) in serum after treatment for cervical cancer warrants further investigation.</p><p><strong>Objectives: </strong>To study the prevalence of serum HPV and correlate its presence with cervical cancer recurrence.</p><p><strong>Methods: </strong>This prospective cross-sectional study recruited 100 patients following treatment of HPV-associated cervical cancer between January 2023 and March 2024 at a tertiary care centre in South India. Patients who had completed treatment within the past 3 years were included. After obtaining consent, a one-time serum sample for HPV detection was analysed using a multiplex real-time PCR AnyplexTM II HPV HR detection assay (Seegene, Seoul, South Korea). The prevalence of serum HPV was correlated with disease recurrence and evaluated by Fisher's Exact test. The log-rank test assessed the differences in disease-free survival between cases with and without measurable serum HPV.</p><p><strong>Results: </strong>Among the 100 patients, the prevalence of serum HPV was 18% (18/100), with genotype 16 being found in 83.3% (15/18) of cases. There were 27 recurrences, of which 15 (55.6%) had detectable serum HPV DNA. Disease recurrence was significantly associated with serum HPV (odds ratio: 29.17, 95% confidence interval: 7.32-116.24). Higher serum HPV DNA levels, as determined by semi-quantification (2 + and 3 +), were associated with an increased hazard ratio for recurrence (58.33, CI: 6.83-498.23). Kaplan-Meier disease-free estimates revealed a significant association between recurrence and serum HPV prevalence (p = 0.000).</p><p><strong>Conclusion: </strong>Serum HPV can be used in the detection of recurrence in post-treatment surveillance of cervical cancer and should be validated in a prospective, longitudinal study.</p>","PeriodicalId":520579,"journal":{"name":"Cancer causes & control : CCC","volume":"37 7","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV in breast cancer: prevalence and comparison with healthy tissue-a systematic review and meta-analysis.","authors":"Pedro Henrique de Souza Wagner, Gustavo Tadeu Freitas Uchôa Matheus, Brenda Luana Rocha Soares Menegat, Ana Luíza Rocha Soares Menegat, Danilo Monteiro Ribeiro, Francisco Cezar Aquino de Moraes","doi":"10.1007/s10552-026-02199-0","DOIUrl":"10.1007/s10552-026-02199-0","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer (BC) is the most common cancer among women worldwide, with over 2.3 million new cases annually. Recent studies suggest that Human Papillomavirus (HPV), a known oncogenic virus, may be involved in BC development. This study investigates HPV prevalence in BC samples and its potential role in tumorigenesis.</p><p><strong>Methods: </strong>Random-effects meta-analyses were conducted to estimate raw proportions and odds ratio (OR), with 95% confidence intervals (CIs). Heterogeneity was assessed using I². Statistical significance was set at p < 0.05. Analyses were performed in R 4.5.0 RESULTS: Our meta-analysis encompassed 82 studies and evaluated 7,683 breast cancer (BC) tissue samples to assess the presence of HPV. The overall prevalence of HPV in BC specimens was estimated at 23% (95%CI: 19%-28%). When stratified by continent, Oceania exhibited the highest regional prevalence at 38%. Comparative analysis between BC tissues and healthy controls revealed a significantly increased likelihood of HPV detection in the cancer group (OR 5.06; P < 0.001). This association remained statistically robust in both case-control (OR 6.34; P < 0.001) and cross-sectional designs (OR 2.83; P < 0.001). Among continents, South America demonstrated the most pronounced association (OR 11.66; P = 0.005). Subgroup analysis based on economic classification indicated that countries with low-income settings had the highest HPV prevalence (34%; 95%CI: 9%-73%). Evaluation by BC subtype revealed that luminal B had the highest HPV-positive rate (44%; 95%CI: 27%-61%).</p><p><strong>Conclusion: </strong>This meta-analysis reveals a global presence of HPV in BC and suggests a possible link. Further well-designed studies are needed to confirm its role in tumorigenesis.</p>","PeriodicalId":520579,"journal":{"name":"Cancer causes & control : CCC","volume":"37 7","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-specific disparities in rural and urban survival among patients with IDH-wildtype glioblastoma: a population-based study.","authors":"Wang Miao, Liu Yang, Jinhu Li, Yuanwei Fu, Yuanda Yang, Xia Yan, Ying Lu, Xin Yang","doi":"10.1007/s10552-026-02198-1","DOIUrl":"10.1007/s10552-026-02198-1","url":null,"abstract":"<p><strong>Background: </strong>Access to subspecialty neuro-oncologic care is uneven across the United States. Whether rural residence is linked to age-specific survival differences in IDH-wildtype glioblastoma (GBM) is unclear.</p><p><strong>Methods: </strong>We used the Surveillance, Epidemiology, and End Results (SEER) 17 database to identify adults (≥ 18 years) with histologically confirmed IDH-wildtype GBM (diagnoses 2018-2022). Rural-urban residence followed 2013 USDA Rural-Urban Continuum Codes (1-3 urban; 4-9 rural). Overall survival (OS) was the primary endpoint. After confirming violation of proportional hazards, we fit multivariable accelerated failure time (AFT) models and report time ratios (TRs) adjusted for area of residence, age group (18-64 vs ≥ 65 years), sex, race, surgery, radiotherapy, and chemotherapy; age-specific effects were assessed by stratification.</p><p><strong>Results: </strong>Among 10,632 patients, 1,193 (11.2%) resided in rural and 9,439 (88.8%) in urban counties. Rural patients were slightly older and were less likely to receive radiotherapy (71.8 vs 76.7%) or chemotherapy (69.2 vs 73.4%); resection rates were similar (84.4 vs 83.8%). One- and two-year OS was 37 and 14% in rural areas versus 45% and 19% in urban areas. In adjusted AFT models, rural residence was associated with shorter survival (TR 0.89 95% CI 0.84-0.95). The association was more evident in adults aged 18-64 years (TR 0.86, 95% CI 0.79-0.94), whereas the estimate in those aged ≥ 65 years was smaller and not statistically significant (TR 0.95, 95% CI 0.87-1.03). Not receiving surgery (TR 0.59), radiotherapy (TR 0.51), or chemotherapy (TR 0.42) was strongly associated with shorter survival.</p><p><strong>Conclusions: </strong>Rural residence was associated with shorter OS in IDH-wildtype GBM. The association was more evident in adults aged 18-64 years.</p>","PeriodicalId":520579,"journal":{"name":"Cancer causes & control : CCC","volume":"37 7","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-diagnosis physical activity in relation to mortality among prostate cancer survivors: a systematic review and meta-analysis.","authors":"Pauline Benker, Alina Hamann, Michael F Leitzmann, Michael J Stein","doi":"10.1007/s10552-026-02197-2","DOIUrl":"10.1007/s10552-026-02197-2","url":null,"abstract":"<p><strong>Background: </strong>Physical activity after cancer diagnosis may reduce mortality. However, systematic evidence for this association for men living with prostate cancer remains limited.</p><p><strong>Methods: </strong>We searched PubMed, Embase, and CINAHL data bases from start to June 2025. Random-effects meta-analyses estimated summary hazard ratios (HRs) and 95% confidence intervals (CI) for all-cause mortality and prostate-cancer-specific mortality to assess the association between post-diagnosis physical activity, measured in metabolic equivalents of task-hours per week (MET-hr/week), and mortality among prostate cancer survivors.</p><p><strong>Results: </strong>We included ten studies with more than 50,144 participants (one study did not report the number of prostate cancer cases included in the meta-analysis) and 28,044 deaths. Higher levels of post-diagnosis physical activity (≥ 7.5 MET-hr/week) were associated with lower all-cause mortality (HR = 0.69; 95% CI: 0.62-0.77), compared to lower levels (< 7.5 MET-hr/week). Meta-analysis of five studies showed an inverse association between post-diagnosis physical activity and prostate cancer-specific mortality (HR = 0.77; 95% CI: 0.66-0.89). Meta-analysis of four studies showed that moderate-to-vigorous physical activity was inversely associated with mortality (HR = 0.62; 95% CI: 0.51-0.74).</p><p><strong>Conclusion: </strong>Higher post-diagnosis physical activity, including activity at higher intensities, was associated with lower all-cause and prostate cancer-specific mortality among men living with prostate cancer. Our findings suggest that physical activity may complement cancer care for prostate cancer patients.</p>","PeriodicalId":520579,"journal":{"name":"Cancer causes & control : CCC","volume":"37 7","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13303671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent disparities in head and neck cancer survival in the United States.","authors":"Ella P Jackert, Swar Vimawala, Liyang Tang, Daniel Kwon, Niels Kokot, Tamara Chambers, Uttam Sinha, Yang Chai, Lihua Liu, Albert Y Han","doi":"10.1007/s10552-026-02196-3","DOIUrl":"10.1007/s10552-026-02196-3","url":null,"abstract":"<p><strong>Purpose: </strong>Head and neck cancer (HNC) is a heterogenous disease with substantial mortality. This study assesses the long-term epidemiologic landscape, demographic disparities, and survival outcomes of HNC.</p><p><strong>Methods: </strong>Adult patients with primary HNC were identified in the Surveillance, Epidemiology, and End Results (SEER) database by International Classification of Diseases for Oncology (ICD-O) codes. The primary outcomes of this study were overall survival (OS) and cancer-specific survival (CSS). Secondary outcomes included primary tumor site distributions and rates of surgery by race and ethnicity. Multivariable Cox regression modeling was utilized to determine predictors of all-cause and HNC-specific mortality.</p><p><strong>Results: </strong>In this cohort of 117,893 head and neck cancer patients, significant racial and ethnic disparities were observed in tumor site, treatment, and outcomes. Black patients were less likely to receive surgery even when accounting for tumor subsite and stage (OR 0.672, 95% CI 0.641-0.705). Five-year overall survival (OS) and cause-specific survival (CSS) were lower in all minority groups (p < 0.001), with Black patients showing the lowest OS (31.3%) and CSS (58.8%). Multivariable analysis confirmed race/ethnicity, low income (HR 1.043, 95% CI 1.018-1.068), and unmarried status (HR 1.327, 95% CI 1.305-1.350) as independent predictors of increased all-cause and HNC-specific mortality.</p><p><strong>Conclusion: </strong>In this most comprehensive and up-to-date analysis of HNC, we demonstrate profound racial and ethnic disparities in tumor sites, treatments, and survival. This study provides critical evidence to guide health policy, resource allocation, and clinical practice aimed at closing longstanding equity gaps in head and neck cancer care.</p>","PeriodicalId":520579,"journal":{"name":"Cancer causes & control : CCC","volume":"37 7","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13303473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mammography screening in Tennessee: a tract-level spatial analysis of geographic and socioeconomic disparities.","authors":"Sima Namin, Jonathan S Wall, R Eric Heidel, Ashton Brooks, Savannah Allen, Jennifer Ferris","doi":"10.1007/s10552-026-02190-9","DOIUrl":"10.1007/s10552-026-02190-9","url":null,"abstract":"<p><strong>Purpose: </strong>Despite improvements in early detection, Tennessee ranks among the top ten states for breast cancer mortality among women. Mammography screening and early diagnosis are critical to reducing mortality, yet access and uptake vary widely across the State. We tested whether access to diagnostic services affected screening in the State.</p><p><strong>Methods: </strong>We merged CDC PLACES estimates of screening among women aged 50-74 with geocoded FDA-certified mammography facilities to derive drive-time categories. Tract covariates included education, poverty, insurance, race/ethnicity, primary care provider density, urban/rural status, and Appalachian designation. We mapped hot/cold spots using Getis-Ord Gi* and fit four nested beta-regression models: geography only, socioeconomic only, combined, and combined plus log-provider density.</p><p><strong>Results: </strong>Median screening prevalence was 74.8%. Hotspots clustered around Memphis, Nashville, and Knoxville; cold spots in Central Appalachian and western floodplain tracts. Geography explained ~ 23% of between-tract variation (pseudo-R² = 0.238); socioeconomic covariates ~ 61% (0.607). In combined models, drive-time and Appalachian effects attenuated. Urban tracts screened 0.72 percentage points (pp) higher than rural, and each 1-pp rise in adults without a high-school diploma predicted - 0.13 pp.</p><p><strong>Conclusion: </strong>Urbanicity and education were the primary drivers of mammography screening disparities in Tennessee. To improve early diagnosis and outcomes, interventions should prioritize educational outreach, poverty reduction, insurance expansion, and improved geographic access, via mobile units or telehealth, targeting remote cold-spot tracts.</p>","PeriodicalId":520579,"journal":{"name":"Cancer causes & control : CCC","volume":"37 7","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13236764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148160278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine-disrupting pesticides and breast cancer incidence in the United States: an ecological analysis.","authors":"Harish Neelam, Furqan Irfan, Robert Wahl, Kelly A Hirko","doi":"10.1007/s10552-026-02188-3","DOIUrl":"10.1007/s10552-026-02188-3","url":null,"abstract":"<p><strong>Purpose: </strong>We examined the associations between county-level endocrine-disrupting pesticide usage and breast cancer incidence, overall and by metropolitan status.</p><p><strong>Methods: </strong>This ecological study used publicly available data from the United States Geological Survey on county-level agricultural pesticide usage (in kilograms). We focused on 38 pesticides with endocrine-disrupting properties relevant in breast cancer etiology, which were categorized by chemical class as follows: carbamates, neonicotinoids, organochlorines, organophosphates, phosphonates, pyrethroids, triazines, and other miscellaneous compounds. The analysis included 2,457 U.S. counties with data on pesticide usage (2001-2015) and age-adjusted breast cancer incidence rates (2016-2020), accounting for a latency period. Metropolitan status was assessed using the 2013 Rural-Urban Continuum Codes. Gamma regression models with a log-link function were used to estimate rate ratios (RR) and 95% confidence intervals (CI) between pesticides (per interquartile range increase) and age-adjusted breast cancer incidence rates, adjusting for county-level covariates including % smoking, % poverty, % unemployed, % no high school diploma, % uninsured, and residential mobility.</p><p><strong>Results: </strong>Total median pesticide use was higher in rural vs. urban counties (17,523 kg vs. 14,743 kg; p < 0.05), with some variation by pesticide class. Pesticide use was associated with slightly higher breast cancer incidence in rural counties (RR = 1.02 (95% CI 1.01, 1.03)), but not in urban counties (RR = 1.00 (95% CI 1.00, 1.00)) (p_int < 0.001). Associations differed by pesticide type.</p><p><strong>Conclusion: </strong>Results suggest modest positive associations between county-level endocrine-disrupting pesticide use and breast cancer incidence in rural U.S. counties, with variation by pesticide type. These findings highlight the need for further research to inform targeted prevention efforts.</p>","PeriodicalId":520579,"journal":{"name":"Cancer causes & control : CCC","volume":"37 7","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13226314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148140652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of rurality and race/ethnicity in thyroid cancer stage at diagnosis and survival among adolescents and young adults in the United States: an analysis of 2000-2021 SEER data.","authors":"Emma Hymel, Josiane Kabayundo, Krishtee Napit, Amelia Nichols, Shinobu Watanabe-Galloway","doi":"10.1007/s10552-026-02183-8","DOIUrl":"10.1007/s10552-026-02183-8","url":null,"abstract":"<p><strong>Purpose: </strong>Relatively few studies have focused on thyroid cancer in the adolescent and young adult (AYA) population. The objective of this study was to examine racial/ethnic and geographic predictors of thyroid cancer stage at diagnosis and survival in the AYA population.</p><p><strong>Methods: </strong>This population-based longitudinal study uses data from the Surveillance, Epidemiology, and End Results (SEER)-22 registries database. Primary cases of malignant thyroid cancer from 2000 to 2021 diagnosed among individuals aged 15-39 were included. Multinomial logistic regression models were used to examine the association between race/ethnicity and rurality (measured using Rural Urban Continuum codes) with stage at diagnosis (measured using SEER summary stages). Cox proportional hazards regression models were used to examine the association between race/ethnicity and rurality and both cancer-specific and all-cause mortality.</p><p><strong>Results: </strong>Our study included 74,215 AYAs with thyroid cancer. Approximately, 8% of the cases resided in rural counties. The association between race/ethnicity and stage at diagnosis differed by rurality (p = 0.010). Among AYAs with thyroid cancer, living in a rural county at diagnosis was associated with an increased hazard of all-cause mortality (aHR = 1.41, 95% CI 1.13-1.76). Additionally, compared to non-Hispanic White AYAs, the hazard of thyroid cancer-specific mortality was highest among non-Hispanic Black (aHR = 3.66, 95% CI 2.37-5.65) and Hispanic (aHR = 1.85, 95% CI 1.32-2.60) AYAs.</p><p><strong>Conclusion: </strong>We observed racial and geographic differences in thyroid cancer stage at diagnosis and survival among AYAs in the USA. Future research should explore the underlying causes of these disparities and identify potential opportunities for intervention.</p>","PeriodicalId":520579,"journal":{"name":"Cancer causes & control : CCC","volume":"37 7","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148102487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between allostatic load and risk of breast carcinoma in situ in the UK biobank.","authors":"Chengsheng Fengfu, Xin Hua, Xiujuan Chen, Mengsi Liu, Aoqiang Chen, Binlong Wan, Hengwen Sun, Huiying Liang, Shasha Du, De-Huan Xie","doi":"10.1007/s10552-026-02186-5","DOIUrl":"10.1007/s10552-026-02186-5","url":null,"abstract":"<p><strong>Background: </strong>The association between allostatic load (AL) and breast carcinoma in situ (BCIS) remains unclear. We investigated this relationship in the UK Biobank while also assessing its role in invasive breast cancer (IDC) for comparison.</p><p><strong>Methods: </strong>Using data from the UK Biobank, we included 159,240 women (40-69 years). AL was derived from 12 biomarkers. Cox proportional hazards models, restricted cubic splines (RCS), and time-dependent ROC curves were used to assess associations with BCIS and IDC.</p><p><strong>Results: </strong>Over a median follow-up of 13.65 years, 1,320 BCIS and 7,197 IDC cases occurred. In fully adjusted models, AL was not associated with BCIS (HR per 1-point increase = 1.004; 95% CI: 0.966-1.042; p  = 0.854). RCS confirmed no non-linear relationship (p = 0.605). Conversely, AL was significantly associated with IDC (HR = 1.018; 95% CI: 1.002-1.035; p  = 0.026), indicating a 1.8% increased risk per unit increase. Predictive utility was minimal (AUC < 0.58), and sensitivity analyses using quintile-based AL scoring validated these findings.</p><p><strong>Conclusion: </strong>While AL is an independent risk factor for IDC, it shows no association with BCIS. These findings suggest that the biological drivers of in-situ lesions differ from those of invasive progression, highlighting AL as an etiologic factor for malignancy rather than a screening tool for early-stage localization.</p>","PeriodicalId":520579,"journal":{"name":"Cancer causes & control : CCC","volume":"37 6","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148038460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}